Pacira BioSciences Net Income
| PCRX Stock | USD 21.00 0.64 3.14% |
As of the 7th of February, Pacira BioSciences holds the insignificant Risk Adjusted Performance, variance of 8.62, and Coefficient Of Variation of (7,324). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pacira BioSciences, as well as the relationship between them.
Pacira BioSciences Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 1.4165 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -114.5 M | -108.8 M | |
| Net Loss | -114.5 M | -108.8 M | |
| Net Income Applicable To Common Shares | 18.3 M | 19.2 M | |
| Net Loss | (1.94) | (2.03) | |
| Net Income Per E B T | 1.42 | 1.17 |
Pacira | Net Income | Build AI portfolio with Pacira Stock |
The evolution of Net Income for Pacira BioSciences provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Pacira BioSciences compares to historical norms and industry peers.
Latest Pacira BioSciences' Net Income Growth Pattern
Below is the plot of the Net Income of Pacira BioSciences over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Pacira BioSciences financial statement analysis. It represents the amount of money remaining after all of Pacira BioSciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Pacira BioSciences' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pacira BioSciences' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (99.56 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Pacira Net Income Regression Statistics
| Arithmetic Mean | (22,514,312) | |
| Geometric Mean | 28,824,075 | |
| Coefficient Of Variation | (283.54) | |
| Mean Deviation | 47,309,940 | |
| Median | (37,949,000) | |
| Standard Deviation | 63,837,483 | |
| Sample Variance | 4075.2T | |
| Range | 260M | |
| R-Value | (0.03) | |
| Mean Square Error | 4343.2T | |
| R-Squared | 0.0008 | |
| Significance | 0.91 | |
| Slope | (368,538) | |
| Total Sum of Squares | 65203.6T |
Pacira Net Income History
Other Fundumenentals of Pacira BioSciences
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Pacira BioSciences Net Income component correlations
Pacira Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Pacira BioSciences is extremely important. It helps to project a fair market value of Pacira Stock properly, considering its historical fundamentals such as Net Income. Since Pacira BioSciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Pacira BioSciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Pacira BioSciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira BioSciences. Anticipated expansion of Pacira directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Pacira BioSciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.48) | Earnings Share 0.47 | Revenue Per Share | Quarterly Revenue Growth 0.065 | Return On Assets |
Understanding Pacira BioSciences requires distinguishing between market price and book value, where the latter reflects Pacira's accounting equity. The concept of intrinsic value - what Pacira BioSciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Pacira BioSciences' price substantially above or below its fundamental value.
It's important to distinguish between Pacira BioSciences' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Pacira BioSciences should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Pacira BioSciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Pacira BioSciences 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Pacira BioSciences' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Pacira BioSciences.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Pacira BioSciences on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Pacira BioSciences or generate 0.0% return on investment in Pacira BioSciences over 90 days. Pacira BioSciences is related to or competes with Cronos, AnaptysBio, Xencor, Oculis Holding, UroGen Pharma, Kodiak Sciences, and Tandem Diabetes. Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practition... More
Pacira BioSciences Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Pacira BioSciences' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Pacira BioSciences upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 14.2 | |||
| Value At Risk | (6.29) | |||
| Potential Upside | 4.5 |
Pacira BioSciences Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pacira BioSciences' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Pacira BioSciences' standard deviation. In reality, there are many statistical measures that can use Pacira BioSciences historical prices to predict the future Pacira BioSciences' volatility.| Risk Adjusted Performance | (0) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.34) | |||
| Treynor Ratio | (0.06) |
Pacira BioSciences February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0) | |||
| Market Risk Adjusted Performance | (0.05) | |||
| Mean Deviation | 2.19 | |||
| Coefficient Of Variation | (7,324) | |||
| Standard Deviation | 2.94 | |||
| Variance | 8.62 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.12) | |||
| Total Risk Alpha | (0.34) | |||
| Treynor Ratio | (0.06) | |||
| Maximum Drawdown | 14.2 | |||
| Value At Risk | (6.29) | |||
| Potential Upside | 4.5 | |||
| Skewness | (1.03) | |||
| Kurtosis | 1.4 |
Pacira BioSciences Backtested Returns
Pacira BioSciences maintains Sharpe Ratio (i.e., Efficiency) of -0.0389, which implies the firm had a -0.0389 % return per unit of risk over the last 3 months. Pacira BioSciences exposes twenty-two different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check Pacira BioSciences' Coefficient Of Variation of (7,324), insignificant risk adjusted performance, and Variance of 8.62 to confirm the risk estimate we provide. The company holds a Beta of 0.85, which implies possible diversification benefits within a given portfolio. Pacira BioSciences returns are very sensitive to returns on the market. As the market goes up or down, Pacira BioSciences is expected to follow. At this point, Pacira BioSciences has a negative expected return of -0.11%. Please make sure to check Pacira BioSciences' mean deviation, treynor ratio, as well as the relationship between the Treynor Ratio and daily balance of power , to decide if Pacira BioSciences performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.58 |
Good reverse predictability
Pacira BioSciences has good reverse predictability. Overlapping area represents the amount of predictability between Pacira BioSciences time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Pacira BioSciences price movement. The serial correlation of -0.58 indicates that roughly 58.0% of current Pacira BioSciences price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.58 | |
| Spearman Rank Test | -0.72 | |
| Residual Average | 0.0 | |
| Price Variance | 6.2 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Pacira Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Pacira BioSciences reported net income of (99.56 Million). This is 129.17% lower than that of the Pharmaceuticals sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 117.44% higher than that of the company.
Pacira Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pacira BioSciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Pacira BioSciences could also be used in its relative valuation, which is a method of valuing Pacira BioSciences by comparing valuation metrics of similar companies.Pacira BioSciences is currently under evaluation in net income category among its peers.
Pacira BioSciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pacira BioSciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pacira BioSciences' managers, analysts, and investors.Environmental | Governance | Social |
Pacira BioSciences Institutional Holders
Institutional Holdings refers to the ownership stake in Pacira BioSciences that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Pacira BioSciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Pacira BioSciences' value.| Shares | Ubs Group Ag | 2025-06-30 | 1 M | Jacobs Levy Equity Management, Inc. | 2025-06-30 | 984.7 K | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 950 K | Polar Capital Holdings Plc | 2025-06-30 | 910.5 K | J. Goldman & Co Lp | 2025-06-30 | 656.6 K | Northern Trust Corp | 2025-06-30 | 585.8 K | Charles Schwab Investment Management Inc | 2025-06-30 | 570.1 K | Wellington Management Company Llp | 2025-06-30 | 545.6 K | Millennium Management Llc | 2025-06-30 | 515 K | Blackrock Inc | 2025-06-30 | 7.8 M | Vanguard Group Inc | 2025-06-30 | 5.4 M |
Pacira Fundamentals
| Return On Equity | 0.029 | ||||
| Return On Asset | 0.0289 | ||||
| Profit Margin | 0.03 % | ||||
| Operating Margin | 0.07 % | ||||
| Current Valuation | 1.02 B | ||||
| Shares Outstanding | 41.1 M | ||||
| Shares Owned By Insiders | 1.90 % | ||||
| Shares Owned By Institutions | 98.04 % | ||||
| Number Of Shares Shorted | 7.11 M | ||||
| Price To Earning | 14.34 X | ||||
| Price To Book | 1.15 X | ||||
| Price To Sales | 1.26 X | ||||
| Revenue | 700.97 M | ||||
| Gross Profit | 470.65 M | ||||
| EBITDA | 29.12 M | ||||
| Net Income | (99.56 M) | ||||
| Cash And Equivalents | 316.39 M | ||||
| Cash Per Share | 6.90 X | ||||
| Total Debt | 638.85 M | ||||
| Debt To Equity | 1.10 % | ||||
| Current Ratio | 3.95 X | ||||
| Book Value Per Share | 16.93 X | ||||
| Cash Flow From Operations | 189.39 M | ||||
| Short Ratio | 7.10 X | ||||
| Earnings Per Share | 0.47 X | ||||
| Price To Earnings To Growth | (3.83) X | ||||
| Target Price | 29.71 | ||||
| Number Of Employees | 788 | ||||
| Beta | 0.23 | ||||
| Market Capitalization | 903.45 M | ||||
| Total Asset | 1.55 B | ||||
| Retained Earnings | (206.36 M) | ||||
| Working Capital | 435.21 M | ||||
| Current Asset | 252.58 M | ||||
| Current Liabilities | 149.79 M | ||||
| Net Asset | 1.55 B |
About Pacira BioSciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pacira BioSciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pacira BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pacira BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Pacira Stock Analysis
When running Pacira BioSciences' price analysis, check to measure Pacira BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences is operating at the current time. Most of Pacira BioSciences' value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences' price. Additionally, you may evaluate how the addition of Pacira BioSciences to your portfolios can decrease your overall portfolio volatility.